Results 51 to 60 of about 949 (151)

Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice

Journal of Internal Medicine, Volume 300, Issue 4, Page 440-460, October 2026.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and a leading cause of cirrhosis, hepatocellular carcinoma, and cardiometabolic morbidity. Often clinically silent until advanced fibrosis develops, management has largely relied on lifestyle interventions, with limited ...
Philip N. Newsome, Saima Ajaz
wiley   +1 more source

Bile acid metabolism and signaling in human and animal health: A One Health perspective

iMetaOmics, Volume 3, Issue 3, September 2026.
Bile acids maintain host homeostasis through enterohepatic circulation, microbial transformation, and bile acid receptor signaling, thereby regulating glucose and lipid metabolism, intestinal barrier integrity, and immunity. These effects support human disease intervention and health‐oriented animal production, reducing drug dependence and residue ...
Lei Li, Shuai Liu, Zhijun Cao, Yangchun Cao, Shengru Wu, Lu Deng, Junhu Yao, Jun Zhang   +7 more
wiley   +1 more source

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

, 2017
Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide.
Das, Nabanita, Prabodha Swain, Ranvir, Ramchandra, Eshani Karmakar, Roy, Sib Sankar, Rathod, Rohan, Wahli, Walter, Nabanita Das, Chitrang Trivedi, Walter Wahli, Jain, Mukul R., Suresh R. Giri, Ramchandra Ranvir, Akshyaya Rath, Pankaj R. Patel, Karmakar, Eshani, Patel, Pankaj R., Giri, Suresh R., Kadam, Shekhar, Bhoi, Bibhuti, Mukul R. Jain, Bibhuti Bhoi, Swain, Prabodha, Rohan Rathod, Shekhar Kadam, Patel, Hiren, Hiren Patel, Trivedi, Chitrang, Rath, Akshyaya, Sib Sankar Roy   +29 more
core   +1 more source

PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis

Journal of International Medical Research, 2023
Objective To undertake a network meta-analysis to compare the relative efficacy of a dual peroxisome proliferator-activated receptor (PPAR)α and PPARγ agonist, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin in patients with non ...
Zhuo-Ya Zhang, Qi Yan, Wen-Hao Wu, Yuan Zhao, Hua Zhang, Jin Li   +5 more
doaj   +1 more source

Exploring the Therapeutic Potential of Oenothera laciniata: Antioxidant, Anti‐Hyperglycemic and Histopathological Activities Using In Vitro and In Vivo Approaches

Food Science &Nutrition, Volume 14, Issue 7, July 2026.
Graphical abstract illustrating the therapeutic potential of Oenothera laciniata: antioxidant, anti‐hyperglycemic and histopathological activities using in vitro and in vivo approaches. ABSTRACT This study investigate the crude ethanolic extract of Oenothera laciniata (EOL) and its solvent fractions n‐hexane (NHOL), dichloromethane (DCMOL), ethyl ...
Dur‐E‐Najaf Khan, Syed Muhammad Mukarram Shah, Muska Mahabat Khan, Rehman Zafar, Muhammad Saeed Jan, Muhammad Ibrar, Abdur Rauf, Yahya S. Al‐Awthan, Omar S. Bahattab, Rakibur Rahman   +9 more
wiley   +1 more source

Saroglitazar protects against cadmium-induced hepatorenal injury in rats by suppressing NF-κB and upregulating Nrf2

Frontiers in Pharmacology
IntroductionCadmium (Cd) toxicity is one of the major public health problems because of its long half-life (10–30 years). Exposure to Cd can cause toxicity that affects several organs, including the liver and the kidney.
Ahmed Alanazi, Hoda E. Kafl, Dalia H. El-Kashef, Ghada M. Suddek   +3 more
doaj   +1 more source

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis

, 2021
Introduction: Patients with primary biliary cholangitis (PBC) without biochemical response to ursodeoxycholic acid (UDCA) are at increased risk of liver-related mortality.
Parmar, Deven, Payan-Olivas, Ramon, Deven Parmar, Farheen Shaikh, Ramon Payan-Olivas, González-Huezo, Ma Saraí, Shaikh, Farheen, Linda E. Muñoz-Espinosa, Pio Cruz-Lopez, Jose L., Ma Saraí González-Huezo, Vuppalanchi, Raj, Jose L. Pio Cruz-Lopez, Raj Vuppalanchi, Muñoz-Espinosa, Linda E.   +13 more
core   +1 more source

From Crisis to Diagnosis: A Case of Hypertriglyceridemic Pancreatitis as the First Clinical Presentation of Type 1 Diabetes [PDF]

Journal of Clinical and Diagnostic Research
Acute Pancreatitis (AP) is a prevalent and rapidly progressive inflammatory disorder of the pancreas, often presenting with abdominal pain and elevated serum pancreatic enzymes.
Subashini Vadivel, Sheetal Nandha Kishore, Jagannath S Dhadwad, Janvi Panchal   +3 more
doaj   +1 more source

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales

Journal of Translational Autoimmunity, 2023
Introduction: Primary biliary cholangitis (PBC) is an autoimmune liver disease involving the small intrahepatic bile ducts; when untreated or undertreated, it may evolve to liver fibrosis and cirrhosis. Ursodeoxycholic Acid (UDCA) is the standard of care
Francesca Colapietro, M. Eric Gershwin, Ana Lleo   +2 more
doaj   +1 more source